Prostate cancer is a condition commonly associated with men worldwide.Androgen deprivation therapy remains one of the targeted therapies.However,after some years,there is biochemical recurrence and metastatic progress...Prostate cancer is a condition commonly associated with men worldwide.Androgen deprivation therapy remains one of the targeted therapies.However,after some years,there is biochemical recurrence and metastatic progression into castration-resistant prostate cancer(CRPC).CRPC cases are treated with second-line androgen deprivation therapy,after which,these CRPCs transdifferentiate to form neuroendocrine prostate cancer(NEPC),a highly aggressive variant of CRPC.NEPC arises via a reversible transdifferentiation process,known as neuroendocrine differentiation(NED),which is associated with altered expression of lineage markers such as decreased expression of androgen receptor and increased expression of neuroendocrine lineage markers including enolase 2,chromogranin A and synaptophysin.The etiological factors and molecular basis for NED are poorly understood,contributing to a lack of adequate molecular biomarkers for its diagnosis and therapy.Therefore,there is a need to fully understand the underlying molecular basis for this cancer.Recent studies have shown that microRNAs(miRNAs)play a key epigenetic role in driving therapy-induced NED in prostate cancer.In this review,we briefly describe the role of miRNAs in prostate cancer and CRPCs,discuss some key players in NEPCs and elaborate on miRNA dysregulation as a key epigenetic process that accompanies therapy-induced NED in metastatic CRPC.This understanding will contribute to better clinical management of the disease.展开更多
基金This work was supported by the US Army Medical Research Acquisition Activity(USAMRAA)through the Idea Development Award under Award(No.W81XWH-18-1-0303)Funding support by the National Cancer Institute at the National Institutes of Health(No.RO1CA177984)is also acknowledged.
文摘Prostate cancer is a condition commonly associated with men worldwide.Androgen deprivation therapy remains one of the targeted therapies.However,after some years,there is biochemical recurrence and metastatic progression into castration-resistant prostate cancer(CRPC).CRPC cases are treated with second-line androgen deprivation therapy,after which,these CRPCs transdifferentiate to form neuroendocrine prostate cancer(NEPC),a highly aggressive variant of CRPC.NEPC arises via a reversible transdifferentiation process,known as neuroendocrine differentiation(NED),which is associated with altered expression of lineage markers such as decreased expression of androgen receptor and increased expression of neuroendocrine lineage markers including enolase 2,chromogranin A and synaptophysin.The etiological factors and molecular basis for NED are poorly understood,contributing to a lack of adequate molecular biomarkers for its diagnosis and therapy.Therefore,there is a need to fully understand the underlying molecular basis for this cancer.Recent studies have shown that microRNAs(miRNAs)play a key epigenetic role in driving therapy-induced NED in prostate cancer.In this review,we briefly describe the role of miRNAs in prostate cancer and CRPCs,discuss some key players in NEPCs and elaborate on miRNA dysregulation as a key epigenetic process that accompanies therapy-induced NED in metastatic CRPC.This understanding will contribute to better clinical management of the disease.
